Exelixis (EXEL) Rating Increased to Sell at ValuEngine

Exelixis (NASDAQ:EXEL) was upgraded by research analysts at ValuEngine from a “strong sell” rating to a “sell” rating in a research report issued on Saturday.

A number of other equities analysts also recently commented on EXEL. BidaskClub downgraded Exelixis from a “sell” rating to a “strong sell” rating in a research report on Saturday, August 11th. Morgan Stanley assumed coverage on Exelixis in a research note on Monday, September 10th. They set an “underweight” rating and a $19.00 target price for the company. Goldman Sachs Group assumed coverage on Exelixis in a research note on Monday, September 17th. They set a “neutral” rating and a $22.00 target price for the company. Guggenheim assumed coverage on Exelixis in a research note on Monday, September 17th. They set a “buy” rating for the company. Finally, Oppenheimer set a $40.00 target price on Exelixis and gave the stock a “buy” rating in a research note on Thursday, November 1st. Two research analysts have rated the stock with a sell rating, three have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the stock. Exelixis presently has an average rating of “Buy” and a consensus price target of $29.44.

Shares of Exelixis stock opened at $20.31 on Friday. Exelixis has a one year low of $13.42 and a one year high of $32.20. The stock has a market cap of $6.07 billion, a PE ratio of 39.82, a P/E/G ratio of 1.20 and a beta of 2.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 8.66 and a quick ratio of 8.54.

Exelixis (NASDAQ:EXEL) last announced its quarterly earnings data on Thursday, November 1st. The biotechnology company reported $0.41 EPS for the quarter, topping the Zacks’ consensus estimate of $0.19 by $0.22. Exelixis had a return on equity of 55.71% and a net margin of 49.53%. The business had revenue of $225.40 million during the quarter, compared to the consensus estimate of $174.14 million. During the same period in the previous year, the company posted $0.26 earnings per share. The business’s revenue for the quarter was up 47.8% on a year-over-year basis. On average, sell-side analysts predict that Exelixis will post 1.3 earnings per share for the current year.

In other Exelixis news, insider Gisela Schwab sold 22,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 4th. The stock was sold at an average price of $18.53, for a total value of $416,925.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CFO Christopher J. Senner sold 8,791 shares of the business’s stock in a transaction that occurred on Friday, November 30th. The shares were sold at an average price of $19.70, for a total value of $173,182.70. The disclosure for this sale can be found here. In the last quarter, insiders sold 251,868 shares of company stock valued at $4,376,122. 4.80% of the stock is owned by company insiders.

Institutional investors have recently added to or reduced their stakes in the company. Rehmann Capital Advisory Group grew its holdings in Exelixis by 1,417.1% during the third quarter. Rehmann Capital Advisory Group now owns 8,966 shares of the biotechnology company’s stock worth $506,000 after acquiring an additional 8,375 shares during the period. Polaris Greystone Financial Group LLC acquired a new position in Exelixis during the third quarter worth $177,000. Oppenheimer Asset Management Inc. acquired a new position in Exelixis during the second quarter worth $217,000. Fox Run Management L.L.C. acquired a new position in Exelixis during the third quarter worth $183,000. Finally, Dynamic Technology Lab Private Ltd acquired a new position in Exelixis during the third quarter worth $222,000. Institutional investors and hedge funds own 79.37% of the company’s stock.

About Exelixis

Exelixis, Inc, a biotechnology company, engages in the discovery, development, and commercialization of new medicines to enhance care and outcomes for people with cancer. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer.

Recommended Story: Book Value Per Share in Stock Trading

To view ValuEngine’s full report, visit ValuEngine’s official website.

Analyst Recommendations for Exelixis (NASDAQ:EXEL)

Receive News & Ratings for Exelixis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Exelixis and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit